Related Experiment Video

Updated: Oct 10, 2025

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

15.8K

Risk-based lung cancer screening eligibility criteria: towards implementation

Kevin Ten Haaf1

  • 1Erasmus MC, University Medical Centre Rotterdam, Department of Public Health, 3000 CA Rotterdam, Netherlands.

The Lancet. Oncology
|December 13, 2021
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Author Spotlight: Expanding Interventional Pulmonology Research with Robotic-Assisted Bronchoscopy
04:10

Author Spotlight: Expanding Interventional Pulmonology Research with Robotic-Assisted Bronchoscopy

Published on: July 19, 2024

870
Author Spotlight: Demonstrating Systematic Endobronchial Ultrasound to New Endoscopists
05:22

Author Spotlight: Demonstrating Systematic Endobronchial Ultrasound to New Endoscopists

Published on: August 11, 2023

2.4K

Related Experiment Videos

Last Updated: Oct 10, 2025

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

15.8K
Author Spotlight: Expanding Interventional Pulmonology Research with Robotic-Assisted Bronchoscopy
04:10

Author Spotlight: Expanding Interventional Pulmonology Research with Robotic-Assisted Bronchoscopy

Published on: July 19, 2024

870
Author Spotlight: Demonstrating Systematic Endobronchial Ultrasound to New Endoscopists
05:22

Author Spotlight: Demonstrating Systematic Endobronchial Ultrasound to New Endoscopists

Published on: August 11, 2023

2.4K

Related Concept Videos

Statistical Methods for Analyzing Epidemiological Data01:25

Statistical Methods for Analyzing Epidemiological Data

599
Epidemiological data primarily involves information on specific populations' occurrence, distribution, and determinants of health and diseases. This data is crucial for understanding disease patterns and impacts, aiding public health decision-making and disease prevention strategies. The analysis of epidemiological data employs various statistical methods to interpret health-related data effectively. Here are some commonly used methods:
599
Criteria for Causality: Bradford Hill Criteria - II01:28

Criteria for Causality: Bradford Hill Criteria - II

763
The Bradford Hill criteria serve as guidelines for establishing causative links in epidemiological research. Beyond Strength, Consistency, Specificity, and Temporality, key criteria also include Biological Gradient, Plausibility, Coherence, Experiment, and Analogy. These principles assist scientists in assessing the likelihood of causation in complex biological contexts. Below is a summary of these concepts:
763

Articles linked to this work by shared authors, journal, and citation graph.

Use and impact of risk-based eligibility models in low-dose computed tomography lung cancer screening: a systematic review.

Public health reviews·2026

The Optimal Lung Cancer Ct Screening Strategy: A Cost-Effectiveness Study Incorporating Nelson Evidence, Evolving Cost of Treatment and Smoking Cessation Interventions.

International journal of cancer·2026

Eligibility for Lung Cancer Screening in Switzerland: A Comparative Analysis of Three Data Sources From Lausanne and the Canton of Vaud.

International journal of public health·2026

Performance of smoking duration-based lung cancer screening eligibility criteria: a comparative modeling study.

Journal of the National Cancer Institute·2026

Eligibility and Prognostic Performance of Smoking Duration-Based Versus Pack-Year-Based U.S. National Lung Cancer Screening Criteria Across Racial and Ethnic Groups.

Annals of internal medicine·2025

Impact of lung cancer screening eligibility criteria on participants' characteristics and healthcare resources.

International journal of cancer·2025

Local management of second ipsilateral breast cancer events after primary breast-conserving therapy: an international Delphi consensus.

The Lancet. Oncology·2026

Consensus statements from the first Gynecologic Cancer InterGroup Cervical Cancer Consensus Conference in Clinical Research.

The Lancet. Oncology·2026

Advancing oncology education in low-income and middle-income African settings: global insights for local action.

The Lancet. Oncology·2026

Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial.

The Lancet. Oncology·2026

Postmastectomy chest wall radiotherapy for breast cancer (SUPREMO): 5-year quality-of-life results from a randomised, controlled, phase 3 trial.

The Lancet. Oncology·2026

Addition of irinotecan to chemoradiotherapy as preoperative treatment for locally advanced rectal cancer (ARISTOTLE): a multicentre, open-label, phase 3, randomised controlled trial.

The Lancet. Oncology·2026

Heat shock protein family D member 1 (HSPD1) modulates ribosome-related pathways and protein synthesis in lung adenocarcinoma.

Molecular and cellular biochemistry·2026

Patient-reported outcomes in clinical trials leading to breast cancer drug approvals: are we making them count?

Breast cancer research and treatment·2026

Sex-specific associations of the bilirubin-to-albumin ratio with lung cancer risk: evidence from Cox regression and causal survival forest analysis.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2026

DHRS2 regulates epithelial-mesenchymal transition in breast cancer cells.

Molecular biology reports·2026

Esculin attenuates cholestatic liver injury and fibrosis in bile duct-ligated rats by modulating oxidative stress, inflammatory responses, and fibrogenic mediators.

Molecular biology reports·2026

Prognostic disparities between radioactive iodine-refractory and non-refractory DTC patients: a cohort study on survival rates and independent risk factors.

Future oncology (London, England)·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us